Literature DB >> 7636742

Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides.

A Malmberg1, N Mohell.   

Abstract

The in vitro receptor binding characteristics of [3H]quinpirole to cloned human dopamine D2A (long isoform) and D3 receptors were investigated and compared with those of rat striatal dopamine receptors. [3H]Quinpirole selectively labeled the high-affinity state of cloned dopamine D2A and striatal D2 receptors with an affinity of about 4 nM. In the striatum, [3H]quinpirole bound to 70% of the receptors labeled by the antagonist [3H]raclopride, whereas the corresponding value for cloned dopamine D2A receptors was 26%. [3H]Quinpirole labeled both the high- and "low-"affinity states of the dopamine D3 receptor with the affinities of 0.6 nM (36% of the receptors) and 7.3 nM, respectively. At all three receptors, sodium decreased the proportion of receptors labeled by [3H]quinpirole, whereas its affinity for the remaining high-affinity sites was not changed. Further addition of guanine nucleotides completely converted the high-affinity binding into low. Thus, even the dopamine D3 receptor was regulated by sodium and guanine nucleotides. Competition studies for [3H]quinpirole and [3H]raclopride binding revealed that the agonists (+)-(R)-7-hydroxy-2-dipropylaminotetralin and quinpirole, previously claimed to be highly dopamine D3-selective (approximately 100-fold), displayed high affinity for the high-affinity agonist states of both dopamine D2 and D3 receptors. When these values were compared, instead of the apparent affinities from the one-site analysis, the dopamine D3-selectivities were 20-fold for (+)-(R)-7-hydroxy-2-dipropylaminotetralin and 8-fold for quinpirole. Thus, it is of importance to consider both high- and low-affinity agonist states when receptor selectivities are evaluated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636742

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens.

Authors:  A Del Arco; F Mora; A H Mohammed; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

2.  Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine.

Authors:  Amy J Ramsey; Aki Laakso; Michel Cyr; Tatyana D Sotnikova; Ali Salahpour; Ivan O Medvedev; Linda A Dykstra; Raul R Gainetdinov; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

Review 3.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

4.  Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons.

Authors:  R D Todd; J Carl; S Harmon; K L O'Malley; J S Perlmutter
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

5.  The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VAChT in the brain of nonhuman primates.

Authors:  Hui Liu; Zonghua Luo; Jiwei Gu; Yi Su; Hubert Flores; Stanley M Parsons; Yun Zhou; Joel S Perlmutter; Zhude Tu
Journal:  Eur J Pharm Sci       Date:  2019-11-15       Impact factor: 4.384

6.  Chronic lithium chloride administration to rats elevates glucose metabolism in wide areas of brain, while potentiating negative effects on metabolism of dopamine D2-like receptor stimulation.

Authors:  Mireille Basselin; Lisa Chang; Stanley I Rapoport
Journal:  Psychopharmacology (Berl)       Date:  2006-06-20       Impact factor: 4.530

Review 7.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

8.  Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Authors:  Ariel Graff-Guerrero; Matthaeus Willeit; Nathalie Ginovart; David Mamo; Romina Mizrahi; Pablo Rusjan; Irina Vitcu; Philip Seeman; Alan A Wilson; Shitij Kapur
Journal:  Hum Brain Mapp       Date:  2008-04       Impact factor: 5.038

9.  Dopaminergic regulation of mate competition aggression and aromatase-Fos colocalization in vasotocin neurons.

Authors:  David Kabelik; Aubrey M Kelly; James L Goodson
Journal:  Neuropharmacology       Date:  2009-06-21       Impact factor: 5.250

10.  Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.

Authors:  Pierre Sokoloff; Ludovic Leriche; Jorge Diaz; Jacques Louvel; René Pumain
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.